Xenon Pharmaceuticals Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Xenon Pharmaceuticals Inc. - Product Pipeline Review - 2012” provides data on the Xenon Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xenon Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xenon Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Xenon Pharmaceuticals Inc.; Xenon Pharmaceuticals Inc. - Key Therapeutics; Xenon Pharmaceuticals Inc. - Pipeline Overview and Promising Molecules; Xenon Pharmaceuticals Inc. - News; Xenon Pharmaceuticals Inc. - Latest Updates; Xenon Pharmaceuticals Inc. - Pipeline; Xenon Pharmaceuticals Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Xenon Pharmaceuticals Inc. - Product Pipeline Review - 2012” provides data on the Xenon Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xenon Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xenon Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Xenon Pharmaceuticals Inc. - Brief Xenon Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xenon Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xenon Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xenon Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Xenon Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xenon Pharmaceuticals Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xenon Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Xenon Pharmaceuticals Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Xenon Pharmaceuticals Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Xenon Pharmaceuticals Inc.; Xenon Pharmaceuticals Inc. - Key Therapeutics; Xenon Pharmaceuticals Inc. - Pipeline Overview and Promising Molecules; Xenon Pharmaceuticals Inc. - News; Xenon Pharmaceuticals Inc. - Latest Updates; Xenon Pharmaceuticals Inc. - Pipeline; Xenon Pharmaceuticals Inc. - Discontinued/Dormant Projects
Xenon Pharmaceuticals Inc. Snapshot
Xenon Pharmaceuticals Inc. Overview
Key Information
Key Facts
Xenon Pharmaceuticals Inc. – Research and Development Overview
Key Therapeutic Areas
Xenon Pharmaceuticals Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xenon Pharmaceuticals Inc. – Pipeline Products Glance
Xenon Pharmaceuticals Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc. – Drug Profiles
Cardiovascular Program
Product Description
Mechanism of Action
R&D Progress
Drug For Anemia Of Inflammation
Product Description
Mechanism of Action
R&D Progress
Oral XEN402
Product Description
Mechanism of Action
R&D Progress
Stearoyl-CoA Desaturase-1 Drug Development Program
Product Description
Mechanism of Action
R&D Progress
Topical XEN402
Product Description
Mechanism of Action
R&D Progress
XEN403
Product Description
Mechanism of Action
R&D Progress
XPF-001
Product Description
Mechanism of Action
R&D Progress
XPF-002
Product Description
Mechanism of Action
R&D Progress
Xenon Pharmaceuticals Inc. – Pipeline Analysis
Xenon Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class
Xenon Pharmaceuticals Inc. – Pipeline Products By Target
Xenon Pharmaceuticals Inc. – Pipeline Products by Route of Administration
Xenon Pharmaceuticals Inc. – Pipeline Products By Mechanism of Action
Xenon Pharmaceuticals Inc. – Recent Pipeline Updates
Xenon Pharmaceuticals Inc. - Dormant Projects
Xenon Pharmaceuticals Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Xenon Pharmaceuticals Inc., Deals Summary
Xenon Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Xenon Pharma Secures $31 Million In Financing
Partnerships
Isis Pharma Enters Into Collaboration With Xenon Pharma
Xenon Pharma Enters Into Collaboration Agreement With DDI
Xenon Enters Into Research Agreement With Roche
Takeda Pharma Enters Into An Agreement With Xenon
Licensing Agreements
Xenon Pharma Enters Into Licensing Agreement With Genentech For Pain Therapeutics
Xenon Pharma Enters Into Cardiovascular Disease Collaboration With Merck
Xenon Enters Into Licensing Agreement With Novartis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Xenon Pharmaceuticals Inc., Key Information
Xenon Pharmaceuticals Inc., Key Facts
Xenon Pharmaceuticals Inc. – Pipeline by Indication, 2012
Xenon Pharmaceuticals Inc. – Pipeline by Stage of Development, 2012
Xenon Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2012
Xenon Pharmaceuticals Inc. – Phase II, 2012
Xenon Pharmaceuticals Inc. – Phase I, 2012
Xenon Pharmaceuticals Inc. – Pre-Clinical, 2012
Xenon Pharmaceuticals Inc. – Discovery, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Therapeutic Class, 2012
Xenon Pharmaceuticals Inc. - Pipeline By Target, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Route of Administration, 2012
Xenon Pharmaceuticals Inc. – Pipeline Products By Mechanism of Action, 2012
Xenon Pharmaceuticals Inc. – Recent Pipeline Updates, 2012
Xenon Pharmaceuticals Inc. - Dormant Developmental Projects,2012
Xenon Pharmaceuticals Inc., Deals Summary
Xenon Pharma Secures $31 Million In Financing
Isis Pharma Enters Into Collaboration With Xenon Pharma
Xenon Pharma Enters Into Collaboration Agreement With DDI
Xenon Enters Into Research Agreement With Roche
Takeda Pharma Enters Into An Agreement With Xenon
Xenon Pharma Enters Into Licensing Agreement With Genentech For Pain Therapeutics
Xenon Pharma Enters Into Cardiovascular Disease Collaboration With Merck
Xenon Enters Into Licensing Agreement With Novartis
LIST OF FIGURES
Xenon Pharmaceuticals Inc. – Pipeline by Indication, 2012
Xenon Pharmaceuticals Inc. – Pipeline by Stage of Development, 2012
Xenon Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Therapeutic Class, 2012
Xenon Pharmaceuticals Inc. - Pipeline By Target, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Route of Administration, 2012
Xenon Pharmaceuticals Inc. - Pipeline Products By Mechanism of Action, 2012
Xenon Pharmaceuticals Inc. Overview
Key Information
Key Facts
Xenon Pharmaceuticals Inc. – Research and Development Overview
Key Therapeutic Areas
Xenon Pharmaceuticals Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xenon Pharmaceuticals Inc. – Pipeline Products Glance
Xenon Pharmaceuticals Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc. – Drug Profiles
Cardiovascular Program
Product Description
Mechanism of Action
R&D Progress
Drug For Anemia Of Inflammation
Product Description
Mechanism of Action
R&D Progress
Oral XEN402
Product Description
Mechanism of Action
R&D Progress
Stearoyl-CoA Desaturase-1 Drug Development Program
Product Description
Mechanism of Action
R&D Progress
Topical XEN402
Product Description
Mechanism of Action
R&D Progress
XEN403
Product Description
Mechanism of Action
R&D Progress
XPF-001
Product Description
Mechanism of Action
R&D Progress
XPF-002
Product Description
Mechanism of Action
R&D Progress
Xenon Pharmaceuticals Inc. – Pipeline Analysis
Xenon Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class
Xenon Pharmaceuticals Inc. – Pipeline Products By Target
Xenon Pharmaceuticals Inc. – Pipeline Products by Route of Administration
Xenon Pharmaceuticals Inc. – Pipeline Products By Mechanism of Action
Xenon Pharmaceuticals Inc. – Recent Pipeline Updates
Xenon Pharmaceuticals Inc. - Dormant Projects
Xenon Pharmaceuticals Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Xenon Pharmaceuticals Inc., Deals Summary
Xenon Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Xenon Pharma Secures $31 Million In Financing
Partnerships
Isis Pharma Enters Into Collaboration With Xenon Pharma
Xenon Pharma Enters Into Collaboration Agreement With DDI
Xenon Enters Into Research Agreement With Roche
Takeda Pharma Enters Into An Agreement With Xenon
Licensing Agreements
Xenon Pharma Enters Into Licensing Agreement With Genentech For Pain Therapeutics
Xenon Pharma Enters Into Cardiovascular Disease Collaboration With Merck
Xenon Enters Into Licensing Agreement With Novartis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Xenon Pharmaceuticals Inc., Key Information
Xenon Pharmaceuticals Inc., Key Facts
Xenon Pharmaceuticals Inc. – Pipeline by Indication, 2012
Xenon Pharmaceuticals Inc. – Pipeline by Stage of Development, 2012
Xenon Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2012
Xenon Pharmaceuticals Inc. – Phase II, 2012
Xenon Pharmaceuticals Inc. – Phase I, 2012
Xenon Pharmaceuticals Inc. – Pre-Clinical, 2012
Xenon Pharmaceuticals Inc. – Discovery, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Therapeutic Class, 2012
Xenon Pharmaceuticals Inc. - Pipeline By Target, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Route of Administration, 2012
Xenon Pharmaceuticals Inc. – Pipeline Products By Mechanism of Action, 2012
Xenon Pharmaceuticals Inc. – Recent Pipeline Updates, 2012
Xenon Pharmaceuticals Inc. - Dormant Developmental Projects,2012
Xenon Pharmaceuticals Inc., Deals Summary
Xenon Pharma Secures $31 Million In Financing
Isis Pharma Enters Into Collaboration With Xenon Pharma
Xenon Pharma Enters Into Collaboration Agreement With DDI
Xenon Enters Into Research Agreement With Roche
Takeda Pharma Enters Into An Agreement With Xenon
Xenon Pharma Enters Into Licensing Agreement With Genentech For Pain Therapeutics
Xenon Pharma Enters Into Cardiovascular Disease Collaboration With Merck
Xenon Enters Into Licensing Agreement With Novartis
LIST OF FIGURES
Xenon Pharmaceuticals Inc. – Pipeline by Indication, 2012
Xenon Pharmaceuticals Inc. – Pipeline by Stage of Development, 2012
Xenon Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Therapeutic Class, 2012
Xenon Pharmaceuticals Inc. - Pipeline By Target, 2012
Xenon Pharmaceuticals Inc. – Pipeline By Route of Administration, 2012
Xenon Pharmaceuticals Inc. - Pipeline Products By Mechanism of Action, 2012
